In Vivo & Ex Vivo Pharmacodynamic Evaluations

Cyagen+In Vivo & Ex Vivo Pharmacodynamic Evaluations


>> Request a Consultation
Our Experts will contact you providing a consultation, information and estimated timeframe to your project needs.

In vivo and ex vivo/in vitro pharmacodynamic evaluation is the key to the pre-clinical research of cell therapy, with in vivo pharmacodynamic experiments being the most critical and difficult to surmount. As a research and development hotspot of cell therapy, the pharmacodynamic evaluation of CAR-T cells is quite different from that of traditional small molecule drugs because of the complexity of the mechanism of CAR-T cells. For example, researchers must determine whether CAR-T cells can effectively bind to predetermined targets to kill target cells, the distribution and duration of CAR-T cells in the body, and much more.

Cyagen one-stop phenotyping analysis platform provides standardized and personalized tumor immune evaluation experiments, covering in vivo and in vitro killing experiments, immunological experiments, functional experiments, expression testing, etc., for CAR-T cell therapy researchers — offering complete pharmacodynamic evaluation services.

Our Pharmacodynamic Evaluation Services


Type Service

In vitro pharmacodynamic evaluation

In vitro killing activity test of CAR-T cell
ADCC/CDC/CTL cytotoxicity test
Immune cell phenotype analysis

CAR-T cell proliferation test

Phenotypic testing of tumor cell

In vivo pharmacodynamic evaluation

CAR-T cell proliferation monitoring in vivo
Pharmacodynamic evaluation of CDX models
Analysis of lymphocytic infiltration

Monitoring of organs pathological changes



  • One-stop evaluation of treatment effects in vivo and in vitro, with consistent and reliable data.
  • Established phenotype analysis platform, able to undertake various phenotype detection experiments.
  • Monitor the clearance of mouse tumors and the survival status of mice in a comprehensive way.
Case Study

Killing activity test results of CAR-T cells

FMC63 CAR-T cells and T cells with different effective target ratios were incubated with Nalm6 cells separately for 48 hours, and then the tumor cell apoptosis was detected by flow cytometry. As shown in the figure, compared with the T cell group, with the conditions of different effective target ratios, FMC63 CAR-T cells all exhibited significantly enhanced specific cytotoxicity to Nalm6 cells.

Figure. 2 The detection result of the positive rate of CD19 antigen on the surface of Nalm6 cells and the test result of the killing of Nalm6 tumor cells by FMC63 CAR-T cells.

Inquiries and Quote Requests

Request a quote now. Alternatively, you can always email or call 800-921-8930 to inquire about our services or obtain a quote for your project.


Related Posts:

>>One-Stop Cell Therapy Research Solutions

>>Viral Vector Generation

>>Cell & Animal Models for Immune-Oncology and CAR-T Cell Therapy